JP Morgan Chase’s Benitec Biopharma BNTC Stock Holding History

JP Morgan Chase’s Portfolio BNTC Stock Details BNTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$79.3K	Buy	7,885 +1,857	+31%	+$21.5K	﹤0.01%	5957
2025 Q4	$81.2K	Buy	6,028 +39	+0.7%	+$539	﹤0.01%	5993
2025 Q3	$84K	Sell	5,989 -849	-12%	-$10.8K	﹤0.01%	6000
2025 Q2	$80K	Buy	+6,838	New	+$95.7K	﹤0.01%	5707
2021 Q1	–	Sell	-4	Closed	–	–	6071
2020 Q4	$0	Hold	4	–	–	﹤0.01%	5639
2020 Q3	$0	Hold	4	–	–	﹤0.01%	5482
2020 Q2	$1K	Hold	4	–	–	﹤0.01%	5287
2020 Q1	$0	Buy	+4	New	+$468	﹤0.01%	5311

Other funds holding BNTC

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

IAM

Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

JP Morgan Chase's BNTC Position: Q1 2026 in Review

JP Morgan Chase increased its Benitec Biopharma (BNTC) stake by 31% in Q1 2026, buying an estimated $21.5K and bringing the position to 7,885 shares worth $79.3K. The position accounts for ﹤0.01% of the portfolio, ranked #5957.

JP Morgan Chase first reported a position in BNTC in Q1 2020 and has held it in 8 quarters since. The position peaked at $84K in Q3 2025. 88 funds tracked by Wall St. Rank hold BNTC as of Q1 2026.

JP Morgan Chase held 7,885 shares of Benitec Biopharma worth $79.3K as of Q1 2026.
JP Morgan Chase bought 1,857 Benitec Biopharma shares in Q1 2026, an estimated $21.5K.
Benitec Biopharma made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #5957 holding.
JP Morgan Chase first reported a position in Benitec Biopharma in Q1 2020 and has held it in 8 quarters since.
JP Morgan Chase's Benitec Biopharma position peaked at $84K in Q3 2025.
88 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.